减瘤性放疗联合阿比特龙治疗转移性去势抵抗性前列腺癌:单中心经验
本研究回顾性分析了149例接受阿比特龙治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,其中30例在阿比特龙失败前接受减瘤性放疗(cRT)。倾向性评分匹配后,cRT组总生存(OS)仍显著改善(中位OS未达到 vs 44.0个月,P=0.009)。亚组分析显示年龄≤65岁、PSA≤20 ng/mL、化疗初治及中危预后患者获益更明显。
要点
- 阿比特龙失败前接受cRT与mCRPC患者OS改善相关。
- 匹配后cRT组中位OS未达到,非cRT组为44.0个月(P=0.009)。
- 年龄≤65岁、化疗初治、PSA≤20 ng/mL及中危预后者获益更显著。
核心结论
- 在阿比特龙失败前接受减瘤性放疗可能改善部分mCRPC患者的生存,尤其是年龄≤65岁、化疗初治、mCRPC诊断时PSA水平相对较低及中危预后患者。
研究设计与样本
- 单中心回顾性研究,纳入2014年2月至2019年2月接受阿比特龙治疗的149例mCRPC患者。
- 接受cRT者(AbiRT组)按1:2倾向性评分匹配至未接受cRT者(non-AbiRT组)。
主要发现
- 中位随访23.5个月,AbiRT组30例(20.1%),non-AbiRT组119例(79.9%)。
- AbiRT组与non-AbiRT组2年OS分别为89.5%和73.5%(P=0.0003)。
- 多因素分析中,AbiRT(HR 0.17;95% CI 0.05-0.58;P=0.004)和预后指数(HR 2.71;95% CI 1.37-5.35;P=0.004)为显著因素。
- 匹配后AbiRT仍与OS改善相关(中位OS未达到 vs 44.0个月,P=0.009)。
- 亚组分析显示年龄≤65岁(HR 0.09;95% CI 0.01-0.65;P=0.018)、PSA≤20 ng/mL(HR 0.29;95% CI 0.09-0.99;P=0.048)、化疗初治(HR 0.20;95% CI 0.06-0.66;P=0.008)及COU-AA-301预后指数中危组(HR 0.13;95% CI 0.03-0.57;P=0.007)患者OS改善。
关键数值与推荐
- cRT在阿比特龙失败前进行;亚组获益人群包括年龄≤65岁、PSA≤20 ng/mL、化疗初治及COU-AA-301预后指数中危组。
临床怎么用
- 对于拟接受阿比特龙治疗的mCRPC患者,可考虑在失败前对符合上述特征者联合减瘤性放疗以改善生存。
局限性
- 单中心回顾性研究,样本量有限,倾向性评分匹配后仍可能存在混杂,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To investigate the potential benefit of cytoreductive radiotherapy (cRT) in metastatic castration-resistant prostate cancer (mCRPC) patients receiving abiraterone. METHODS: From February 2014 to February 2019, 149 mCRPC patients treated with abiraterone were identified. Patients receiving cRT before abiraterone failure (AbiRT group) were matched by one-to-two propensity score to patients without cRT before abiraterone failure (non-AbiRT group). RESULTS: The median follow-up was 23.5 months. Thirty patients (20.1%) were in the AbiRT group, whereas 119 patients (79.9%) were in the non-AbiRT group. The 2-year OS of patients managed by AbiRT and non-AbiRT were 89.5% and 73.5%, respectively (P = 0.0003). On multivariate analysis, only AbiRT (HR 0.17; 95% CI 0.05-0.58; P = 0.004) and prognostic index (HR 2.71; 95% CI 1.37-5.35; P = 0.004) were significant factors. After matching, AbiRT continued to be associated with improved OS (median OS not reached vs. 44.0 months, P = 0.009). Subgroup analysis revealed that patients aged ≤ 65 years (HR 0.09; 95% CI 0.01-0.65; P = 0.018), PSA ≤ 20 ng/mL (HR 0.29; 95% CI 0.09-0.99; P = 0.048), chemotherapy-naïve upon abiraterone treatment (HR 0.20; 95% CI 0.06-0.66; P = 0.008) and in intermediate prognosis groups by COU-AA-301 prognostic index (HR 0.13; 95% CI 0.03-0.57; P = 0.007) had improved OS with AbiRT. CONCLUSIONS: cRT before resistance to abiraterone may improve survival in selected mCRPC patients: age ≤ 65 years old, chemotherapy-naïve, with a relatively low PSA level at the diagnosis of mCRPC and intermediate prognosis.
引用
- Liu Y, Long W, Zhang Z, et al. Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience. Radiat Oncol. 2021. PMID: 33407637. doi:10.1186/s13014-020-01732-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。